|
|
 | | | |
- close
- close
- close
- close
This excerpt taken from the CYTK DEF 14A filed Apr 1, 2009. BOARD OF
DIRECTORS
The following table sets forth for each Class I Director,
each Class II Director, and each Class III Director of
the Company, in alphabetical order, and their ages and present
positions with the Company as of March 31, 2009.
There is no family relationship between any director and
executive officer of the Company.
Robert I. Blum was appointed as our President and Chief
Executive Officer and as a member of our Board of Directors in
January 2007. Previous to that appointment, Mr. Blum served
as our President from February 2006 to January 2007. He served
as our Executive Vice President, Corporate Development and
Commercial Operations and Chief Business Officer from September
2004 to February 2006. From January 2004 to September 2004, he
served as our Executive Vice President, Corporate Development
and Finance and Chief Financial Officer. From October 2001 to
December 2003, he served as our Senior Vice President, Corporate
Development and Finance and Chief Financial Officer. From July
1998 to September 2001, Mr. Blum was our Vice President,
Business Development. Prior to joining us in July 1998, he was
Director, Marketing at COR Therapeutics, Inc., a
biopharmaceutical company, since 1996. From 1991 to 1996, he was
Director, Business Development at COR Therapeutics. Prior to
that, Mr. Blum performed roles of increasing responsibility
in sales, marketing and other pharmaceutical business functions
at Marion Laboratories, Inc. and Syntex Corporation.
Mr. Blum received B.A. degrees in Human Biology and
Economics from Stanford University and an M.B.A. from Harvard
Business School.
Stephen Dow has served as a member of our Board of
Directors since April 1998 and was appointed Lead Outside
Director of the Board of Directors in February 2009.
Mr. Dow has been a General Partner with Sevin Rosen Funds,
a venture capital firm, since 1983. Since 1989, Mr. Dow has
served on the Board of Directors of Citrix Systems Inc., an
enterprise software company. Mr. Dow received a B.A. in
Economics and an M.B.A. from Stanford University.
Denise M. Gilbert, Ph.D. has served as a member of
our Board of Directors since May 2008. From 2001 to 2002, she
served as Chief Executive Officer of Entigen Corporation, a
private life science information technology company. From 1995
to 1999, Dr. Gilbert served as Chief Financial Officer and
Executive Vice President of Incyte Pharmaceuticals (now Incyte
Corporation). From 1993 to 1995, Dr. Gilbert was Chief
Financial Officer and Executive Vice President of Affymax Inc.
From 1986 through 1993, Dr. Gilbert was a Managing Director
and senior biotechnology analyst at Smith Barney
Harris & Upham and Vice President and biotechnology
analyst at Montgomery Securities. Dr. Gilbert currently
serves on the Board of Directors of Dynavax Technologies
Corporation, a biopharmaceutical company. Dr. Gilbert holds
a B.S. from Cornell University and a Ph.D. in Cell and
Developmental Biology from Harvard University.
A. Grant Heidrich, III has served as a member
of our Board of Directors since April 1998. Mr. Heidrich is
currently partner emeritus at Mayfield Fund, a venture capital
firm. From 1983 to 2006, Mr. Heidrich served as a Managing
Director of certain Mayfield funds. From 1993 to May 2008,
Mr. Heidrich served as a member of the
Table of Contents
Board of Directors of Millennium Pharmaceuticals, Inc., a
biopharmaceutical company (now a subsidiary of Takeda
Pharmaceutical Company Limited). Mr. Heidrich received a
B.A. in Human Biology from Stanford University and an M.B.A.
from Columbia University.
John T. Henderson has served a member of our Board of
Directors since February 2009. Since December 2000,
Dr. Henderson has served as a consultant to the
pharmaceutical industry as president of Futurepharm LLC. Until
his retirement in December 2000, Dr. Henderson was with
Pfizer Inc. for over 25 years, most recently as a Vice
President in the Pfizer Pharmaceuticals Group.
Dr. Henderson previously held Vice Presidential level
positions with Pfizer in Research and Development in Europe and
later in Japan. He was also Vice President, Medical for
Pfizer’s Europe, U.S. and International
Pharmaceuticals groups. Dr. Henderson currently serves as
the Chairman of the Board of Directors of Myriad Genetics, Inc.,
a healthcare company. Dr. Henderson earned his
bachelor’s and medical degrees from the University of
Edinburgh and is a Fellow of the Royal College of Physicians
(Ed.).
Mark McDade has served as a member of our Board of
Directors since April 2005 and as Lead Outside Director of the
Board of Directors from January 2007 to February 2009.
Mr. McDade currently serves as Executive Vice President of
Global Operations at UCB, S.A., a biopharmaceutical company,
which he joined in April 2008. From 2002 to 2007, he served as
Chief Executive Officer and a member of the Board of Directors
of PDL BioPharma Inc., a biotechnology company. From December
2000 until November 2002, he served as Chief Executive Officer
of Signature BioScience, Inc., a biopharmaceutical company.
Prior to that, he co-founded and served as Chief Operating
Officer at Corixa Corporation, a biopharmaceutical company, from
September 1994 until December 1998, and as President and Chief
Operating Officer from January 1999 to November 2000.
Mr. McDade received a B.A. in History from Dartmouth
College and an M.B.A. from the Harvard Business School.
James H. Sabry, M.D., Ph.D. co-founded the
Company in August 1997 and has been a member of our Board of
Directors since the Company’s inception. Dr. Sabry has
served as Chairman of the Board of Directors and Chairman of our
Scientific Advisory Board since April 2008. From January 2007
through March 2008, Dr. Sabry was Executive Chairman of our
Board of Directors. Previous to that appointment, Dr. Sabry
served as our Chief Executive Officer, and from August 1997
through January 2006, he served as both our President and Chief
Executive Officer. Dr. Sabry has been the President and
Chief Executive Officer of Arete Therapeutics, Inc., a privately
held pharmaceutical company, since July 2008 and a member of
Arete’s Board of Directors since March 2008. Prior to
co-founding Cytokinetics, Dr. Sabry held faculty positions
at the University of California, San Francisco, from 1989
to 1998, and Harvard Medical School from 1984 to 1987.
Dr. Sabry received an M.D. from Queen’s University and
a Ph.D. in Cell Biology from the University of California,
San Francisco.
Michael Schmertzler has served as a member of our Board
of Directors since April 2003. Mr. Schmertzler has been the
Chief Executive Officer and a member of the Board of Directors
of Kolltan Pharmaceuticals, a privately held biotechnology
company, since January 2009. Since 2001, Mr. Schmertzler
has been a Managing Director of Aries Advisors, LLC, the
sub-advisor to Credit Suisse First Boston Equity Partners, L.P.,
a private equity fund, and the Chair of the investment
committee. From 1997 to 2001, Mr. Schmertzler was Co-Head
of United States and Canadian Private Equity at Credit Suisse
First Boston, an investment banking company. Prior to 1997,
Mr. Schmertzler held various management positions with
Morgan Stanley and its affiliates, including President of Morgan
Stanley Leveraged Capital Funds and Managing Director, and was
Managing Director and Chief Financial Officer of Lehman Brothers
Kuhn Loeb, an investment banking firm. Mr. Schmertzler has
been an Adjunct Professor at Yale University since 1997.
Mr. Schmertzler received a B.A. from Yale College in
Molecular Biophysics and Biochemistry, History and City Planning
and an M.B.A. from the Harvard Business School.
James A. Spudich, Ph.D. co-founded our company in
August 1997 and has served as a member of our Board of Directors
since the Company’s inception. From September 1998 to
September 1999, he served as our Principal Scientist.
Dr. Spudich is the Douglass M. Nola Leishman Professor in
Cardiovascular Disease and Professor of Biochemistry and
Developmental Biology at Stanford University, where he has been
a member of the faculty since 1977. From 1994 to 1998,
Dr. Spudich served as Chairman of Stanford
University’s Department of Biochemistry. From 1979 to 1984,
he was Chairman of Stanford’s Department of Structural
Biology. He was elected a member of the American Academy of Arts
and Sciences in 1997 and a member of the National Academy of
Sciences in 1991. Dr. Spudich is also a member of our
Scientific Advisory Board. Dr. Spudich received a B.S. in
Chemistry from the University of Illinois and a Ph.D. in
Biochemistry from Stanford University.
Table of Contents
This excerpt taken from the CYTK DEF 14A filed Apr 2, 2008. BOARD OF
DIRECTORS
The following table sets forth for each Class I Director,
each Class II Director, and each Class III Director of
the Company, in alphabetical order, their ages and present
positions with the Company as of March 31, 2008.
Table of Contents
There is no family relationship between any director and
executive officer of the Company.
Robert I. Blum was appointed as our President and Chief
Executive Officer in January 2007. Previous to that appointment,
Mr. Blum served as our President from February 2006 to
January 2007. He served as our Executive Vice President,
Corporate Development and Commercial Operations and Chief
Business Officer from September 2004 to February 2006. From
January 2004 to September 2004, he served as our Executive Vice
President, Corporate Development and Finance and Chief Financial
Officer. From October 2001 to December 2003, he served as our
Senior Vice President, Corporate Development and Finance and
Chief Financial Officer. From July 1998 to September 2001,
Mr. Blum was our Vice President, Business Development.
Prior to joining us in July 1998, he was Director, Marketing at
COR Therapeutics, Inc., a biopharmaceutical company, since 1996.
From 1991 to 1996, he was Director, Business Development at COR
Therapeutics. Prior to that, Mr. Blum performed roles of
increasing responsibility in sales, marketing and other
pharmaceutical business functions at Marion Laboratories, Inc.
and Syntex Corporation. Mr. Blum received B.A. degrees in
Human Biology and Economics from Stanford University and an
M.B.A. from Harvard Business School.
Stephen Dow has served as a member of our Board of
Directors since April 1998. Mr. Dow has been a General
Partner with Sevin Rosen Funds, a venture capital firm, since
1983. Since 1989, Mr. Dow has served on the Board of
Directors of Citrix Systems Inc., an enterprise software
company. Mr. Dow received a B.A. in Economics and an M.B.A.
from Stanford University.
A. Grant Heidrich, III has served as a member
of our Board of Directors since April 1998. Mr. Heidrich is
currently partner emeritus at Mayfield Fund, a venture capital
firm. From 1983 to 2006, Mr. Heidrich served as a Managing
Director of certain Mayfield funds. Mr. Heidrich currently
serves as a member of the Board of Directors of Millennium
Pharmaceuticals, Inc., a biopharmaceutical company.
Mr. Heidrich received a B.A. in Human Biology from Stanford
University and an M.B.A. from Columbia University.
Charles Homcy, M.D. has served as a member of our
Board of Directors since February 2003. Since November 2003,
Dr. Homcy has served as Chief Executive Officer of Portola
Pharmaceuticals, Inc., a biopharmaceutical company. From January
2003 to November 2003, Dr. Homcy served as Senior Research
and Development Advisor of Millennium Pharmaceuticals, Inc. From
February 2002 to December 2002, Dr. Homcy served as the
President of Research and Development at Millennium
Pharmaceuticals. From 1995 to February 2002, he served as
Executive Vice President, Research and Development of COR
Therapeutics, Inc., where he served as a member of the Board of
Directors from 1998 to February 2002. From 1994 to March 1995,
Dr. Homcy was President of the Medical Research Division of
American Cyanamid Company-Lederle Laboratories (now a division
of Wyeth-Ayerst Laboratories). From 1990 to 1994, Dr. Homcy
was Executive Director of the Cardiovascular and Central Nervous
System Research Section at Lederle Laboratories. Dr. Homcy
currently serves on the Board of Directors of Millennium
Pharmaceuticals, Kosan Biosciences, Inc. and Geron Corporation.
Dr. Homcy received an A.B. in Biology and an M.D. from
Johns Hopkins University.
Mark McDade has served as a member of our Board of
Directors since April 2005. In January 2007, Mr. McDade was
appointed Lead Outside Director of the Board of Directors.
Mr. McDade served as Chief Executive Officer and a director
of PDL BioPharma Inc., a biotechnology company from November
2002 until October 2007. From December 2000 until November 2002,
he served as Chief Executive Officer of Signature BioScience,
Inc., a biopharmaceutical company. Prior to that, he co-founded
and served as Chief Operating Officer at Corixa Corporation, a
biopharmaceutical company, from September 1994 until December
1998, and as President and Chief Operating Officer from January
1999 to November 2000. Mr. McDade also serves on the Board
of Directors of two privately held companies. Mr. McDade
received a B.A. in History from Dartmouth College and an M.B.A.
from the Harvard Business School.
James H. Sabry, M.D., Ph.D. co-founded the
Company in August 1997 and has been a member of our Board of
Directors since the Company’s inception. Effective
April 1, 2008, Dr. Sabry serves as Chairman of the
Board of Directors and a member of our Scientific Advisory
Board. From January 2007 through March 2008, Dr. Sabry was
Executive Chairman of the Board of Directors. Previous to that
appointment, Dr. Sabry served as our Chief Executive
Officer, and from August 1997 through January 2006, he served as
both our President and Chief Executive Officer. Prior to
co-founding the Company, Dr. Sabry held faculty positions
at the University of
Table of Contents
California, San Francisco, from 1989 to 1998, and Harvard
Medical School from 1984 to 1987. Dr. Sabry received an
M.D. from Queen’s University and a Ph.D. in Cell Biology
from the University of California, San Francisco.
Michael Schmertzler has served as a member of our Board
of Directors since April 2003. Since 2001, Mr. Schmertzler
has been a Managing Director of Aries Advisors, LLC, the
sub-advisor to Credit Suisse First Boston Equity Partners, L.P.,
a private equity fund, and the Chair of the investment
committee. From 1997 to 2001, Mr. Schmertzler was Co-Head
of United States and Canadian Private Equity at Credit Suisse
First Boston, an investment banking company. Prior to 1997,
Mr. Schmertzler held various management positions with
Morgan Stanley and its affiliates, including President of Morgan
Stanley Leveraged Capital Funds and Managing Director, and was
Managing Director and Chief Financial Officer of Lehman Brothers
Kuhn Loeb, an investment banking firm. Mr. Schmertzler has
been an Adjunct Professor at Yale University since 1997.
Mr. Schmertzler received a B.A. from Yale College in
Molecular Biophysics and Biochemistry, History and City Planning
and an M.B.A. from the Harvard Business School.
James A. Spudich, Ph.D. co-founded our company in
August 1997 and has served as a member of our Board of Directors
since the Company’s inception. From September 1998 to
September 1999, he served as our Principal Scientist.
Dr. Spudich is the Douglass M. Nola Leishman Professor in
Cardiovascular Disease and Professor of Biochemistry and
Developmental Biology at Stanford University, where he has been
a member of the faculty since 1977. From 1994 to 1998,
Dr. Spudich served as Chairman of Stanford
University’s Department of Biochemistry. From 1979 to 1984,
he was Chairman of Stanford’s Department of Structural
Biology. He was elected a member of the American Academy of Arts
and Sciences in 1997 and a member of the National Academy of
Sciences in 1991. Dr. Spudich is also a member of our
Scientific Advisory Board. Dr. Spudich received a B.S. in
Chemistry from the University of Illinois and a Ph.D. in
Biochemistry from Stanford University.
This excerpt taken from the CYTK DEF 14A filed Apr 5, 2007. BOARD OF
DIRECTORS
The following table sets forth for each Class I Director,
each Class II Director, and each Class III Director of
the Company, in alphabetical order, their ages and present
positions with the Company as of March 31, 2007.
There is no family relationship between any director and
executive officer of the Company.
Robert I. Blum was appointed as our President and Chief
Executive Officer in January 2007. Previous to that appointment,
Mr. Blum served as our President from February 2006 to
January 2007. He served as our Executive Vice President,
Corporate Development and Commercial Operations and Chief
Business Officer from September 2004 to February 2006. From
January 2004 to September 2004, he served as our Executive Vice
President, Corporate Development and Finance and Chief Financial
Officer. From October 2001 to December 2003, he served as our
Senior Vice President, Corporate Development and Finance and
Chief Financial Officer. From July 1998 to September 2001,
Mr. Blum was our Vice President, Business Development.
Prior to joining us in July 1998, he was Director, Marketing at
COR Therapeutics, Inc., a biopharmaceutical company, since 1996.
From 1991 to 1996, he was Director, Business Development at COR
Therapeutics. Prior to that, Mr. Blum performed roles of
increasing responsibility in sales, marketing and other
pharmaceutical business functions at Marion Laboratories, Inc.
and Syntex Corporation. Mr. Blum received B.A. degrees in
Human Biology and Economics from Stanford University and an
M.B.A. from Harvard Business School.
Stephen Dow has served as a member of our Board of
Directors since April 1998. Mr. Dow has been a General
Partner with Sevin Rosen Funds, a venture capital firm, since
1983. Since 1989, Mr. Dow has served on the Board of
Directors of Citrix Systems Inc., an enterprise software
company. Mr. Dow received a B.A. in Economics and an M.B.A.
from Stanford University.
A. Grant Heidrich, III has served as a member
of our Board of Directors since April 1998. Mr. Heidrich
has been a Managing Director of certain funds at Mayfield Fund,
a venture capital firm, since 1983. Mr. Heidrich currently
serves as a member of the Board of Directors of Millennium
Pharmaceuticals, Inc., a biopharmaceutical company, and
PolyFuel, Inc., a fuel cell technology company.
Mr. Heidrich received a B.A. in Human Biology from Stanford
University and an M.B.A. from Columbia University.
Charles Homcy, M.D. has served as a member of our
Board of Directors since February 2003. Since November 2003,
Dr. Homcy has served as Chief Executive Officer of Portola
Pharmaceuticals, Inc., a biopharmaceutical company. From January
2003 to November 2003, Dr. Homcy served as Senior Research
and Development Advisor of Millennium Pharmaceuticals, Inc. From
February 2002 to December 2002, Dr. Homcy served as the
President of Research and Development at Millennium
Pharmaceuticals. From 1995 to February 2002, he served as
Executive Vice President, Research and Development of COR
Therapeutics, Inc., where he served as a member of the Board of
Directors from 1998 to February 2002. From 1994 to March 1995,
Dr. Homcy was President of the Medical Research Division of
American Cyanamid Company-Lederle Laboratories (now a division
of Wyeth-Ayerst
Table of Contents
Laboratories). From 1990 to 1994, Dr. Homcy was Executive
Director of the Cardiovascular and Central Nervous System
Research Section at Lederle Laboratories. Dr. Homcy
currently serves on the Board of Directors of Millennium
Pharmaceuticals, Kosan Biosciences, Inc. and Geron Corporation.
Dr. Homcy received an A.B. in Biology and an M.D. from
Johns Hopkins University.
Mark McDade has served as a member of our Board of
Directors since April 2005. In January 2007, Mr. McDade was
appointed Lead Outside Director of the Board of Directors. Since
November 2002, Mr. McDade has served as Chief Executive
Officer and a director of PDL BioPharma Inc., a biotechnology
company. From December 2000 until November 2002, he served as
Chief Executive Officer of Signature BioScience, Inc., a
biopharmaceutical company. Prior to that, he co-founded and
served as Chief Operating Officer at Corixa Corporation, a
biopharmaceutical company, from September 1994 until December
1998, and as President and Chief Operating Officer from January
1999 to November 2000. Mr. McDade also serves on the Board
of Directors of two privately held companies. Mr. McDade
received a B.A. in History from Dartmouth College and an M.B.A.
from the Harvard Business School.
James H. Sabry, M.D., Ph.D. co-founded the
Company in August 1997 and has been a member of our Board of
Directors since the Company’s inception. In January 2007,
Dr. Sabry was appointed Executive Chairman of the Board of
Directors. Previous to that appointment, Dr. Sabry served
as our Chief Executive Officer, and from August 1997 through
January 2006, he served as both our President and Chief
Executive Officer. Prior to co-founding the Company,
Dr. Sabry held faculty positions at the University of
California, San Francisco, from 1989 to 1998, and Harvard
Medical School from 1984 to 1987. Dr. Sabry received an
M.D. from Queens University and a Ph.D. in Cell Biology from the
University of California, San Francisco.
Michael Schmertzler has served as a member of our Board
of Directors since April 2003. Since 2001, Mr. Schmertzler
has been a Managing Director of Aries Advisors, LLC, the
sub-advisor
to Credit Suisse First Boston Equity Partners, L.P., a private
equity fund, and the Chair of the investment committee. From
1997 to 2001, Mr. Schmertzler was Co-Head of United States
and Canadian Private Equity at Credit Suisse First Boston, an
investment banking company. Prior to 1997, Mr. Schmertzler
held various management positions with Morgan Stanley and its
affiliates, including President of Morgan Stanley Leveraged
Capital Funds and Managing Director, and was Managing Director
and Chief Financial Officer of Lehman Brothers Kuhn Loeb, an
investment banking firm. Mr. Schmertzler has been an
Adjunct Professor at Yale University since 1997.
Mr. Schmertzler received a B.A. from Yale College in
Molecular Biophysics and Biochemistry, History and City Planning
and an M.B.A. from the Harvard Business School.
James A. Spudich, Ph.D. co-founded our company in
August 1997 and has served as a member of our Board of Directors
since the Company’s inception. From September 1998 to
September 1999, he served as our Principal Scientist.
Dr. Spudich is the Douglass M. Nola Leishman Professor
in Cardiovascular Disease and Professor of Biochemistry and
Developmental Biology at Stanford University, where he has been
a member of the faculty since 1977. From 1994 to 1998,
Dr. Spudich served as Chairman of Stanford
University’s Department of Biochemistry. From 1979 to 1984,
he was Chairman of Stanford’s Department of Structural
Biology. He was elected a member of the American Academy of Arts
and Sciences in 1997 and a member of the National Academy of
Sciences in 1991. Dr. Spudich is also a member of our
Scientific Advisory Board. Dr. Spudich received a B.S. in
Chemistry from the University of Illinois and a Ph.D. in
Biochemistry from Stanford University.
| EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
